AR099671A1 - ANHIBINE OF INHIBINE a, CODIFYING GENE OF INHIBINE a, CODIFYING GENE OF FUSION PROTEIN, PROCESS OF OBTAINING THE INHIBINE ANTIGEN a, ANTIGEN COMPOSITION, USE OF THE INHIBINE ANTIGEN a AND USE OF THE ANTIGEN COMPOSITION - Google Patents

ANHIBINE OF INHIBINE a, CODIFYING GENE OF INHIBINE a, CODIFYING GENE OF FUSION PROTEIN, PROCESS OF OBTAINING THE INHIBINE ANTIGEN a, ANTIGEN COMPOSITION, USE OF THE INHIBINE ANTIGEN a AND USE OF THE ANTIGEN COMPOSITION

Info

Publication number
AR099671A1
AR099671A1 ARP150100658A ARP150100658A AR099671A1 AR 099671 A1 AR099671 A1 AR 099671A1 AR P150100658 A ARP150100658 A AR P150100658A AR P150100658 A ARP150100658 A AR P150100658A AR 099671 A1 AR099671 A1 AR 099671A1
Authority
AR
Argentina
Prior art keywords
inhibine
antigen
inhibin
fusion protein
composition
Prior art date
Application number
ARP150100658A
Other languages
Spanish (es)
Inventor
Marroquin Quelopana Miryam
Raul Romero Ramos Celso
Original Assignee
Ouro Fino Saúde Animal Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ouro Fino Saúde Animal Ltda filed Critical Ouro Fino Saúde Animal Ltda
Publication of AR099671A1 publication Critical patent/AR099671A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una proteína inhibina a modificada, sus fragmentos antigénicos y proteína de fusión comprendiendo la misma, así como a una composición antigénica comprendiendo inhibina a modificada y/o un fragmento antigénico de la misma y/o una proteína de fusión comprendiendo inhibina a modificada, al proceso de producción de la proteína inhibina a modificada, sus fragmentos antigénicos y proteína de fusión comprendiendo la misma, y al uso de la inhibina a modificada, sus fragmentos antigénicos; o proteína de fusión comprendiendo inhibina a, y al uso de la composición antigénica en el aumento de la ovulación de animales, especialmente mamíferos y aves. La presente se fundamenta en la modificación de la secuencia madura de la subunidad a de la inhibina de Bos taurus, específicamente en el segmento de la extremidad C-terminal que, además de la modificación de algunos aminoácidos, pasa a tener las dos regiones más inmunogénicas en ese segmento. Gen codificante.This refers to an inhibin to modified protein, its antigenic fragments and fusion protein comprising the same, as well as to an antigenic composition comprising inhibin to modified and / or an antigenic fragment thereof and / or a fusion protein comprising inhibin. to modified, to the process of production of the inhibin to modified protein, its antigenic fragments and fusion protein comprising the same, and to the use of the inhibin to modified, its antigenic fragments; or fusion protein comprising inhibin a, and the use of the antigenic composition in the increase of ovulation of animals, especially mammals and birds. This is based on the modification of the mature sequence of the a subunit of Bos taurus inhibin, specifically in the segment of the C-terminal limb that, in addition to the modification of some amino acids, happens to have the two most immunogenic regions in that segment. Coding gene.

ARP150100658A 2014-03-07 2015-03-05 ANHIBINE OF INHIBINE a, CODIFYING GENE OF INHIBINE a, CODIFYING GENE OF FUSION PROTEIN, PROCESS OF OBTAINING THE INHIBINE ANTIGEN a, ANTIGEN COMPOSITION, USE OF THE INHIBINE ANTIGEN a AND USE OF THE ANTIGEN COMPOSITION AR099671A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102014005376A BR102014005376A2 (en) 2014-03-07 2014-03-07 inhibin alpha antigen, inhibin alpha coding gene, fusion protein encoding gene, process of obtaining inhibin alpha antigen, antigenic composition, use of inhibin alpha antigen, and use of antigenic composition

Publications (1)

Publication Number Publication Date
AR099671A1 true AR099671A1 (en) 2016-08-10

Family

ID=54054284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100658A AR099671A1 (en) 2014-03-07 2015-03-05 ANHIBINE OF INHIBINE a, CODIFYING GENE OF INHIBINE a, CODIFYING GENE OF FUSION PROTEIN, PROCESS OF OBTAINING THE INHIBINE ANTIGEN a, ANTIGEN COMPOSITION, USE OF THE INHIBINE ANTIGEN a AND USE OF THE ANTIGEN COMPOSITION

Country Status (4)

Country Link
AR (1) AR099671A1 (en)
BR (1) BR102014005376A2 (en)
UY (1) UY36020A (en)
WO (1) WO2015131254A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
KR940004077B1 (en) * 1985-04-18 1994-05-11 바이오테크놀로지 오스트레일리아 프로프라이어터리 리밋티드 Recombinantinhbin
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4864019A (en) * 1985-11-08 1989-09-05 The Salk Institute For Biological Studies Antibodies to inhibin and conjugates produced therefrom
ES2065673T3 (en) * 1990-01-08 1995-02-16 Genentech Inc PROCEDURE TO INCREASE FERTILITY IN FEMALES.
US20040220098A1 (en) * 1994-02-28 2004-11-04 Satterlee Daniel G. Inhibin compositions and methods of enhancing fertility and growth
PT804219E (en) * 1994-02-28 2002-12-31 Agritech Technologies Ltd INIBINE COMPOSITIONS AND METHODS FOR THEIR USE
JPH07238097A (en) * 1994-09-07 1995-09-12 Masao Igarashi Igg antibody comprising inhibin as antigen
JP2899534B2 (en) * 1994-12-09 1999-06-02 全国農業協同組合連合会 Method of inducing superovulation in cattle
JP2006523180A (en) * 2002-11-07 2006-10-12 アグリテック テクノロジー リミテッド Novel inhibin-related multi-antigen peptide composition that promotes productivity in birds
BRPI0506043A (en) * 2005-07-12 2007-03-13 Univ Fed Do Rio Grande Do Sul animal evaluation and selection process
CN101407781A (en) * 2008-12-01 2009-04-15 华中农业大学 Inhibin DNA vaccine capable of improving animal fertility, and preparation and use thereof

Also Published As

Publication number Publication date
UY36020A (en) 2015-09-30
WO2015131254A1 (en) 2015-09-11
BR102014005376A2 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
AR122964A2 (en) PEPTIDES USEFUL IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER TYPES OF CANCER
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201791148A1 (en) METHOD FOR DETERMINING THE ABSOLUTE QUANTITIES OF HLA-RESTRICTED CANCER PEPTIDES FORMED OUT OF THE NATURAL PROCESSING
EA201791706A1 (en) ICOS BINDING PROTEINS
AR104635A1 (en) COMPOSITIONS BASED ON IMMUNOGENIC LYSTERY THAT INCLUDE ANTIGEN AND TRUNCATED FUSIONS AND METHODS OF USE OF THESE
CL2018000232A1 (en) Peptide mixture (divisional application 201601405)
ES2722773T3 (en) Modified Meningococcal fHbp Polypeptides
PE20081686A1 (en) FUSION PROTEINS INCLUDING AN ANTIGEN PRAME (DAGE)
BR112019010275A2 (en) recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus
UY35444A (en) ANTI-TNF ALFA MUTATES AND METHODS FOR USE
EA201692279A1 (en) METHOD FOR REDUCING IMMUNOGENIC PROTEIN AND PEPTIDE
AR114565A1 (en) FC IL-22 FUSION PROTEINS AND METHODS OF USE
CL2017000053A1 (en) Β-protofibril binding antibodies
PE20151978A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDIC COMPONENT WITH ANT-INFLAMMATORY PROPERTIES AND USES OF THE SAME
CL2017003228A1 (en) Ras protein mutant fragments
BR112017009790A2 (en) anti-ang2 antibodies and methods of use
EA201990298A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
CU20170112A7 (en) VARIOUS POLYPEPTIDES DIVIDING TOXINS FROM FUSARIUM, ADDITIVE CONTAINING THESE VARIATIONS AND THEIR USE, AS WELL AS PROCEDURES FOR DIVISION OF TOXINS FROM FUSARIUM
BR112017001966A2 (en) "Method for producing variants with an improved sialylated fc"
PE20161221A1 (en) IL-21 ANTIBODIES
MX2020004552A (en) Vaccine t cell enhancer.
BR112016016103A2 (en) COMPOSITION OF MYCOBACTERIAL ANTIGENS
PE20151866A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDE COMPONENT WITH ADIPONECTIN STIMULATING PROPERTIES AND USES OF THE SAME
SV2017005545A (en) VARIOUS FUSIONS III OF THE EPIDERMIC-MESOTHELINE GROWTH FACTOR RECEPTOR AND METHODS TO USE THE SAME
ES2721159T3 (en) Novel MHC-independent tumor associated antigens

Legal Events

Date Code Title Description
FB Suspension of granting procedure